Comparing the current results to its competitors, Bicycle Therapeutics Plc reported Revenue decrease in the 1 quarter 2026 year on year by -91.11 %, despite the revenue increase by the most of its competitors of 21.26 %, recorded in the same quarter.
Bicycle Therapeutics Plc, slower than the average decrease reported by the company's competitors of -28.98 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -28.98 %
Bicycle Therapeutics Plc's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapid technological advancements and a focus on proprietary products. It faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. Its product candidates compete with existing and future therapies. Notably, several companies, including Pfizer Inc. (which acquired Seagen in December 2023), Eli Lilly and Company, and Mabwell Therapeutics, Inc., are developing programs targeting Nectin-4 and EphA2. Competitors often possess greater financial, technical, and human resources, along with more experience in drug discovery, regulatory approvals, and commercialization, which may enhance their ability to bring products to market.
December 13, 2024
Breakthrough Developments in NECTIN4-Targeted Therapy Amid Revenue Challenges for Bicycle Therapeutics Bicycle Therapeutics Reports Promising Zelenectide Pevedotin Data While Grappling with Market Competition In an era where oncology therapeutics are undergoing transformative innovations, Bicycle Therapeutics plc (NASDAQ: BCYC) has carved a niche by leveraging its pioneering bicyclic peptide technology. The Cambridge, England, and Boston-based firm recently announced striking developments at the 2024 San Antonio Breast Cancer Symposium (SABCS), where it presented breakthrough data on zelenectide pevedotin. Enthusing the clinical community, the data showcased enhanced anti-tumor activity of zelenectide peved...
August 6, 2024
Bicycle Therapeutics (NASDAQ: BCYC) continues to drive innovation in the pharmaceutical industry with its unique bicyclic peptide (Bicycle) technology. This article provides an overview of the company s recent business progress and financial results for the second quarter of 2024, as well as highlights upcoming presentations of promising clinical data at the American Society for Clinical Oncology (ASCO) Annual Meeting. Bicycle Therapeutics plc, a trailblazer in pharmaceutical innovation, leverages its proprietary bicyclic peptide (Bicycle) technology to create a novel class of therapeutics with unique mechanistic characteristics. The company has made significant strides in both business development and clin...
Vera Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing innovative therapies for patients with rare and serious diseases. Their business model focuses on researching and developing novel drug candidates, conducting clinical trials, and obtaining regulatory approvals to bring their products to market. By targeting niche patient populations with unmet medical needs, they aim to provide effective treatment options and improve patient outcomes.
Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.
Summit Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of rare diseases. The company employs a research-driven business model, leveraging its proprietary technologies and expertise to identify and develop novel drugs targeting specific genetic mutations associated with these rare diseases. Summit Therapeutics Inc aims to bring its drug candidates through preclinical and clinical development stages and ultimately secure regulatory approval and commercialize them to benefit patients in need.
Acelyrin Inc is a technology company that focuses on providing cutting-edge solutions in the healthcare industry. Their business model is centered around developing innovative software and hardware products that improve patient outcomes, enhance operational efficiency, and drive cost savings for healthcare organizations. By offering a range of advanced tools and services, Acelyrin Inc aims to revolutionize the healthcare sector and contribute to the overall advancement of digital health.
Scpharmaceuticals Inc's business model involves the development and commercialization of innovative pharmaceutical products. They aim to create and bring to market novel therapies that improve patient access, safety, and convenience. Their approach focuses on leveraging their proprietary technology to develop and deliver drugs in a unique and effective manner.
Sources:
Bicycle Therapeutics Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bicycle Therapeutics Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
